150 related articles for article (PubMed ID: 24768118)
21. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
[TBL] [Abstract][Full Text] [Related]
22. High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features.
Sun PL; Seol H; Lee HJ; Yoo SB; Kim H; Xu X; Jheon S; Lee CT; Lee JS; Chung JH
J Thorac Oncol; 2012 Feb; 7(2):323-30. PubMed ID: 22237264
[TBL] [Abstract][Full Text] [Related]
23. Relevance of EGFR mutation with micropapillary pattern according to the novel IASLC/ATS/ERS lung adenocarcinoma classification and correlation with prognosis in Chinese patients.
Chao L; Yi-Sheng H; Yu C; Li-Xu Y; Xin-Lan L; Dong-Lan L; Jie C; Yi-Lon W; Hui LY
Lung Cancer; 2014 Nov; 86(2):164-9. PubMed ID: 25236981
[TBL] [Abstract][Full Text] [Related]
24. High-grade lung adenocarcinoma with fetal lung-like morphology: clinicopathologic, immunohistochemical, and molecular analyses of 17 cases.
Morita S; Yoshida A; Goto A; Ota S; Tsuta K; Yokozawa K; Asamura H; Nakajima J; Takai D; Mori M; Oka T; Tamaru J; Itoyama S; Furuta K; Fukayama M; Tsuda H
Am J Surg Pathol; 2013 Jun; 37(6):924-32. PubMed ID: 23629442
[TBL] [Abstract][Full Text] [Related]
25. [To evaluate the clinicopathologic characteristics and outcome of tumor cells spreading through air spaces in patients with adenocarcinoma of lung].
Sun PL; Liu JN; Cao LQ; Yao M; Gao HW
Zhonghua Bing Li Xue Za Zhi; 2017 May; 46(5):303-308. PubMed ID: 28468034
[No Abstract] [Full Text] [Related]
26. Clinicopathologic characteristics and prognostic significance of EGFR and p53 mutations in surgically resected lung adenocarcinomas ≤2 cm in maximal dimension.
Lin MW; Wu CT; Shih JY; Chang YL; Yang PC
J Surg Oncol; 2014 Aug; 110(2):99-106. PubMed ID: 24788590
[TBL] [Abstract][Full Text] [Related]
27. High expression of programmed cell death 1 ligand 1 in lung adenocarcinoma is a poor prognostic factor particularly in smokers and wild-type epidermal growth-factor receptor cases.
Mori S; Motoi N; Ninomiya H; Matsuura Y; Nakao M; Mun M; Okumura S; Nishio M; Morikawa T; Ishikawa Y
Pathol Int; 2017 Jan; 67(1):37-44. PubMed ID: 27976463
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathological and prognostic features of surgically resected pathological stage I lung adenocarcinoma harboring epidermal growth factor receptor and K-ras mutation.
Kaseda K; Asakura K; Kazama A; Ozawa Y
Thorac Cancer; 2017 May; 8(3):229-237. PubMed ID: 28322512
[TBL] [Abstract][Full Text] [Related]
29. Association of IASLC/ATS/ERS Histologic Subtypes of Lung Adenocarcinoma With Epidermal Growth Factor Receptor Mutations in 320 Resected Cases.
Nakamura H; Saji H; Shinmyo T; Tagaya R; Kurimoto N; Koizumi H; Takagi M
Clin Lung Cancer; 2015 May; 16(3):209-15. PubMed ID: 25467929
[TBL] [Abstract][Full Text] [Related]
30. Cytomorphologic features of advanced lung adenocarcinomas tested for EGFR and KRAS mutations: a retrospective review of 50 cases.
Marotti JD; Schwab MC; McNulty NJ; Rigas JR; DeLong PA; Memoli VA; Tsongalis GJ; Padmanabhan V
Diagn Cytopathol; 2013 Jan; 41(1):15-21. PubMed ID: 21681971
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathological, Radiological, and Molecular Features of Primary Lung Adenocarcinoma with Morule-Like Components.
Wang LL; Ding L; Zhao P; Guan JJ; Ji XB; Zhou XL; Shao SH; Zou YW; Fu WW; Lin DL
Dis Markers; 2021; 2021():9186056. PubMed ID: 34234879
[TBL] [Abstract][Full Text] [Related]
32. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
Li H; Pan Y; Li Y; Li C; Wang R; Hu H; Zhang Y; Ye T; Wang L; Shen L; Sun Y; Chen H
Lung Cancer; 2013 Jan; 79(1):8-13. PubMed ID: 23098378
[TBL] [Abstract][Full Text] [Related]
33. EGFR, KRAS, BRAF and HER2 testing in metastatic lung adenocarcinoma: Value of testing on samples with poor specimen adequacy and analysis of discrepancies.
Forest F; Stachowicz ML; Casteillo F; Karpathiou G; Gouzy-Grosjean F; Guilaubey C; Cottier M; Beal J; Clemenson A; Péoc'h M
Exp Mol Pathol; 2017 Dec; 103(3):306-310. PubMed ID: 29175303
[TBL] [Abstract][Full Text] [Related]
34. Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
Shen YC; Tseng GC; Tu CY; Chen WC; Liao WC; Chen WC; Li CH; Chen HJ; Hsia TC
Lung Cancer; 2017 Aug; 110():56-62. PubMed ID: 28676220
[TBL] [Abstract][Full Text] [Related]
35. Clinicopathological features of lung adenocarcinoma with KRAS mutations.
Kakegawa S; Shimizu K; Sugano M; Miyamae Y; Kaira K; Araki T; Nakano T; Kamiyoshihara M; Kawashima O; Takeyoshi I
Cancer; 2011 Sep; 117(18):4257-66. PubMed ID: 21387273
[TBL] [Abstract][Full Text] [Related]
36. EGFR L858R mutation is associated with lung adenocarcinoma patients with dominant ground-glass opacity.
Yang Y; Yang Y; Zhou X; Song X; Liu M; He W; Wang H; Wu C; Fei K; Jiang G
Lung Cancer; 2015 Mar; 87(3):272-7. PubMed ID: 25582278
[TBL] [Abstract][Full Text] [Related]
37. Epidermal growth factor receptor mutations are linked to skip N2 lymph node metastasis in resected non-small-cell lung cancer adenocarcinomas.
Guerrera F; Renaud S; Tabbó F; Voegeli' AC; Filosso PL; Legrain M; Boita M; Schaeffer M; Beau-Faller M; Ruffini E; Falcoz PE; Inghirami G; Oliaro A; Massard G
Eur J Cardiothorac Surg; 2017 Apr; 51(4):680-688. PubMed ID: 28329143
[TBL] [Abstract][Full Text] [Related]
38. The correlation of the International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) classification with prognosis and EGFR mutation in lung adenocarcinoma.
Yanagawa N; Shiono S; Abiko M; Ogata SY; Sato T; Tamura G
Ann Thorac Surg; 2014 Aug; 98(2):453-8. PubMed ID: 24961844
[TBL] [Abstract][Full Text] [Related]
39. Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma.
Cai W; Lin D; Wu C; Li X; Zhao C; Zheng L; Chuai S; Fei K; Zhou C; Hirsch FR
J Clin Oncol; 2015 Nov; 33(32):3701-9. PubMed ID: 26416997
[TBL] [Abstract][Full Text] [Related]
40. A single institution-based retrospective study of surgically treated bronchioloalveolar adenocarcinoma of the lung: clinicopathologic analysis, molecular features, and possible pitfalls in routine practice.
Casali C; Rossi G; Marchioni A; Sartori G; Maselli F; Longo L; Tallarico E; Morandi U
J Thorac Oncol; 2010 Jun; 5(6):830-6. PubMed ID: 20521350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
